Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. (May 2023)

• Record Type: Journal Article
• Authors: Kolind, Shannon; Gaetano, Laura; Assemlal, Haz-Edine; Bernasconi, Corrado; Bonati, Ulrike; Elliott, Colm; Hagenbuch, Niels; Magon, Stefano; Arnold, Douglas L; Traboulsee, Anthony
• Is Part Of: Multiple sclerosis. Volume 29:Number 6(2023)
• Page Start: 741
• Page End: 747
• Publication Date: 2023-05
• Subjects: Relapsing multiple sclerosis -- ocrelizumab -- brain volume loss; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585231162586
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by two major and interconnected hallmarks: inflammation and progressive neurodegeneration. Objective: The aim of this work was to compare neurodegenerative processes, in the form of global and regional brain volume loss rates, in healthy controls (HCs) and in patients with relapsing MS (RMS) treated with ocrelizumab, which suppresses acute inflammation. Methods: Whole brain, white matter, cortical gray matter, thalamic, and cerebellar volume loss rates were assessed in 44 HCs that were part of a substudy in the OPERA II randomized controlled trial (NCT01412333) and 59 patients with RMS enrolled in the same substudy as well as age- and sex-matched patients in OPERA I (NCT01247324) and II. Volume loss rates were computed using random coefficients models over a period of 2 years. Results: Ocrelizumab-treated patients showed global and regional brain volume loss rates that were approaching that of HCs. Conclusion: These findings are consistent with an important role of inflammation on overall tissue loss and the role of ocrelizumab in reducing this phenomenon.